Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Tango Therapeutics, Inc.
Mayo Clinic
Erasca, Inc.
University of California, San Francisco
QuantumLeap Healthcare Collaborative
Mayo Clinic
Essen Biotech
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Alabama at Birmingham
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Mayo Clinic
University of Southern California
Memorial Sloan Kettering Cancer Center
Institut Bergonié
Maria Sklodowska-Curie National Research Institute of Oncology
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Transgene
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
Amgen
ImmVira Pharma Co. Ltd
University of California, Irvine
Valo Therapeutics Oy
Epkin
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.
Yonsei University
University of Iowa
OncoC4, Inc.
Memorial Sloan Kettering Cancer Center